Fig. 1.

Evaluation of tumor microenvironmental status in gliomas with ESTIMATE algorithm. The stromal score, immune score and estimate score showed different distribution patterns in WHO grades (A), IDH mutation status (B), 1p/19q codeletion status (C), MGMT promoter methylation status (D) and molecular subtypes (E). The KM survival curve revealed that patients with high stromal score (F), immune score (G) or estimate score (H) lived significantly shorter than patients with low score (p < 0.0001, log-rank test)